Mar 05, 2012, 10.28 AM | Source: Reuters
Cipla said it had received government notices seeking Rs 425 crore due to over pricing of certain drugs.
The demands are contrary to the orders passed by the Supreme Court of India and are related to the same drugs under litigation, the drugmaker said in a statement.
The company has received a legal advice which says the entire amount demanded by the National Pharmaceutical Pricing Authority (NPPA) is not tenable and sustainable, Cipla said.
NPPA is a government body that fines drugmakers in India if they over price certain drugs that have been identified under the national list of essential medicines.
Cipla stock price
On February 05, 2016, Cipla closed at Rs 569.95, up Rs 19.70, or 3.58 percent. The 52-week high of the share was Rs 752.45 and the 52-week low was Rs 540.55.
The company's trailing 12-month (TTM) EPS was at Rs 20.05 per share as per the quarter ended September 2015. The stock's price-to-earnings (P/E) ratio was 28.43. The latest book value of the company is Rs 137.94 per share. At current value, the price-to-book value of the company is 4.13.
Analysts doubt veracity of US API import ban report
A report today said the US government has made it
Cipla Q3 results on Feb 10, 2016
Cipla board meeting will be held on February 10, 2
Cipla patriarch Y K Hamied increases stake in co to over 20%
Y KHamied (80), who is the Non-Executive Chairman
Super Six short term picks for February 1
Manas Jaiswal of manasjaiswal.com advises buying I
Cipla top bet from pharma space, says Jai Bala
Jai Bala of Cashthechaos.com is of the view that C
Cipla gets CCI nod to sell 26% in consumer healthcare biz
In November last year, the company signed an agree
Buy United Breweries; short Cipla: Gaurav Bissa
Gaurav Bissa of LKP Securities recommends buying U
Sensex, Nifty flat; L&T, Adani, Cipla top gainers
L&T, Adani Ports, Cipla, Lupin and Wipro are top g